Agilent is regaining growth momentum with stronger margins, rising guidance, and a recurring-revenue mix that supports quality earnings. The stock looks attractive on fundamentals, but valuation leaves less room for execution missteps.
Agilent Technologies(A) looks like a high-quality compounder that is back in a healthier operating rhythm, but the stock is no longer cheap enough to ignore execution risk. The core bull case rests on three facts. First, fiscal Q2 2026 revenue reached $1.83B, up 10.0% reported and 6.3% core, while non-GAAP EPS of $1.49 grew 14% y/y. Second, management raised full-year FY2026 guidance to $7.39B to $7.49B in revenue and $6.00 to $6.10 in non-GAAP EPS. Third, Agilent’s business mix is anchored by recurring consumables, software, and services, with Agilent CrossLab generating $2.908B of FY2025 revenue, or 41.9% of total sales.
That combination matters. Agilent is not just selling expensive boxes into a cyclical capex market. It is monetizing a large installed base through service contracts, consumables, workflow software, and regulated lab support. In FY2025, revenue rose to $6.948B from $6.510B in FY2024, while free cash flow reached $1.15B on the annual cash flow statement and FCF yield stood at 6.01%. Gross margin remained above 52%, operating margin was 22.9% on a trailing basis, and ROE was 19.95%. Those are the marks of a business with real pricing power and sticky workflows.
The caution flag is valuation discipline. Agilent trades at 25.57x trailing earnings and 19.38x forward earnings, with an EV/revenue multiple of 4.83x and a PEG ratio of 1.20. Those numbers are not extreme for a durable life-science tools franchise, but they do assume that the recent growth reacceleration and margin expansion continue. For a balanced, moderate-risk investor with a medium-term horizon, Agilent fits better as a Buy on pullbacks than as a chase-at-any-price momentum name. The business is stronger than the stock’s 52-week low of $108.35 implies, but the shares are not so discounted that execution can slip without consequence.
Agilent Technologies(A) is a life sciences tools and diagnostics company headquartered in Santa Clara, California. The company was incorporated in 1999, employs about 18,000 people, and operates globally across life sciences, diagnostics, and applied chemical markets. It sells analytical instruments, consumables, software, and services to pharma and biotech customers, clinical and pathology labs, chemical and advanced materials customers, food testing labs, environmental labs, and academic and government institutions.
The company reports through three operating segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. In FY2025, total revenue was $6.948B. Agilent CrossLab was the largest segment at $2.908B, or 41.9% of revenue. Life Sciences and Diagnostics Markets generated $2.726B, or 39.2%. Applied Markets contributed $1.314B, or 18.9%.
That segment mix says a lot about the business model. CrossLab gives Agilent a recurring revenue engine tied to service, consumables, and software. Life Sciences and Diagnostics gives it exposure to pharma, pathology, and companion diagnostics. Applied Markets gives it a more industrial and environmental leg, including spectroscopy, gas chromatography, and forensics. The result is a diversified portfolio that can absorb weakness in one end market better than a pure-play instrument vendor.
That management claim lines up with the numbers. FY2025 revenue grew 6.7% reported from FY2024, and Q2 FY2026 continued that recovery with $1.83B of revenue and 26.4% operating margin on a non-GAAP basis. The company’s 52-week range of $108.35 to $159.62 also shows how sentiment has swung between cyclical concern and renewed confidence. With a market cap of $32.74B, Agilent sits in the middle ground of healthcare tools: large enough to have scale, but still small enough to gain share in focused workflows.
Life Sciences and Diagnostics Markets is Agilent’s core growth engine in regulated and innovation-heavy workflows. In FY2025, the segment generated $2.726B of revenue. In Q2 FY2026, management said LDG revenue grew 9% on a core basis, led by low double-digit growth in LC and LCMS and in cancer diagnostics. Specialty CDMO, now called the advanced therapeutics division, also posted high single-digit growth, and management expects that business to deliver mid-teens growth in FY2026.
This segment matters because it ties Agilent to biopharma R&D, manufacturing quality control, pathology, and companion diagnostics. Those are attractive markets because they combine technical complexity with regulatory friction. Once an instrument, method, or software stack is validated in a workflow, customers do not switch casually. That creates a moat built on inconvenience, compliance, and uptime. In plain English, the lab would rather pay than revalidate.
Agilent CrossLab is the largest segment and arguably the most important one for earnings quality. It produced $2.908B in FY2025 revenue. In Q2 FY2026, ACG grew 2% on a core basis, with ex-China growth at the high end of mid single digits and consumables growth in the high single digits. The slower reported segment growth versus LDG is not a flaw. CrossLab is the ballast. It monetizes the installed base through repairs, maintenance, compliance support, training, software, asset management, and consumables. That recurring stream tends to be steadier than instrument demand.
Applied Markets generated $1.314B in FY2025 revenue and posted 11% core growth in Q2 FY2026. Management said the quarter was driven by double-digit spectroscopy demand tied to semiconductor production and by the TSA airport security contract. The segment also benefited from strong forensics demand, where management cited greater than 50% growth in the quarter and multiple large tender wins in Asia and Europe.
The segment picture is attractive because all three legs are contributing. LDG brings growth, CrossLab brings resilience, and Applied Markets adds upside from industrial and security applications. Management now expects mid single-digit growth for all three business segments in FY2026. That is a healthier setup than a story built on one hot product cycle.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Agilent’s flagship product story is not a single blockbuster device. It is a workflow stack built around chromatography, mass spectrometry, diagnostics platforms, consumables, and software. Still, several products stand out as current growth drivers.
The Infinity III LC platform is one of the clearest examples. Management tied recent instrument strength and replacement-cycle momentum to customer-centric innovation embedded in Infinity III LC. In Q2 FY2026, Agilent reported market-leading low double-digit growth in LC and LCMS, and management said instrument orders met or exceeded revenue for the ninth consecutive quarter, with book-to-bill above 1.0. That is a strong sign that the platform is not just shipping, but replenishing demand.
The new 9500 triple quad ICP-MS platform is another important launch. Management described it as a differentiated architecture with a patented dual cell system, an air mode that removes the need for dedicated oxygen gas, and OpenLab integration that automates method migration. The commercial point is simple: higher throughput, lower operating cost, and less workflow complexity. In a lab budget, that is the difference between a nice instrument and a justified purchase order.
Agilent’s upgraded flagship gas chromatographs also matter because they solve a real customer pain point. Management said the new GCs offer up to 30% faster oven cool down, higher throughput, built-in intelligence for proactive maintenance, and technology to conserve or eliminate helium gas. In a market where helium supply remains a real operating issue, that is not marketing glitter. It is a practical cost and uptime advantage.
On the consumables side, Altura Ultra Inert LC columns are gaining traction quickly. Management said they grew more than 50% sequentially and reached 75% of the top 20 biopharma accounts. That is exactly the kind of installed-base pull-through investors want to see. Instruments get the headlines, but columns and consumables often carry the cleaner economics.
OpenLab CDS version 3.0 adds another layer. The software now supports chromatography, mass spec, and spectroscopy systems across the portfolio, including high-resolution mass spec for the first time. Software is not the largest revenue line today, but it deepens workflow integration and raises switching costs. Once the data layer is embedded, the hardware sale becomes part of a larger system.
Agilent’s competitive advantage comes from installed base, workflow integration, service depth, and operating discipline. The company is not the biggest player in life science tools, but it does not need to be the biggest to be dangerous. It needs to be the vendor that is hardest to rip out.
Management repeatedly tied recent performance to the Ignite operating system. In Q2 FY2026, Ignite helped deliver approximately 200 bps of pricing, ahead of the initial full-year goal of 100 bps. It also contributed to margin expansion, procurement savings, supply-chain resilience, and faster product launches. Manufacturing overhead fell by more than 50 bps y/y, and the 9500 ICP-MS launch was pulled forward by a full quarter.
That matters because pricing power in this industry is earned, not declared. Labs tolerate price increases when the vendor controls a validated workflow, supports uptime, and reduces total cost of ownership. Agilent’s gross margin of 52.3%, operating margin of 22.86%, and ROA of 8.53% suggest that the company has that kind of economic position.
The moat is also visible in CrossLab. Services, consumables, and software create recurring revenue tied to the installed base. In the 2025 investor presentation, consumables made up 65% of product-type mix and services 35%, with consumables, services, and informatics up 100 bps y/y. That mix shift supports steadier earnings and better customer retention.
Agilent is also leaning into AI and digital capabilities. Management launched a China Innovation Center to strengthen R&D in digital, AI, and automation. The company also built an AI-enabled supply chain control tower that improved schedule attainment, order conversion ratios, and cycle times. Those are not flashy consumer-AI claims. They are the sort of back-end improvements that widen operating leverage over time.
The risk is scale. Agilent competes against larger peers such as Thermo Fisher, Danaher, Waters, Bruker, and Shimadzu. Those companies have broad portfolios and deep budgets. Agilent’s answer is focus, customer intimacy, and workflow breadth across instruments, consumables, software, and service. So far, the recent share gains in LC, LCMS, diagnostics, and forensics suggest that answer is working.
Operations have become a bigger part of the Agilent story. In Q2 FY2026, management credited Ignite for stronger supply-chain agility, better manufacturing discipline, and full mitigation of incremental tariffs that began in late spring. The company said strategic manufacturing moves and targeted price adjustments fully offset the operating profit impact of those tariffs.
That is an important detail because life science tools companies often get squeezed when freight, tariffs, or component shortages rise. Agilent’s response was not to absorb the hit quietly. It used pricing, sourcing, and manufacturing changes to protect margins. Q2 gross margin reached 55.0%, up 90 bps y/y, while operating margin rose 130 bps y/y to 26.4% on a non-GAAP basis.
The company also cited a quick response to logistics challenges and material shortages arising from the Middle East conflict. That does not remove geopolitical risk, but it does show that Agilent’s operating model is more adaptive than it was a few years ago. In a business that ships instruments, parts, reagents, and service support globally, supply-chain resilience is not a side issue. It is part of the product.
Capital allocation has remained measured. In Q2 FY2026, Agilent generated $277M of operating cash flow, spent $76M on capex, repurchased $65M of stock, and paid $72M in dividends. For FY2026, management expects capex of about $450M, down from prior guidance of $500M, while keeping operating cash flow guidance at $1.2B to $1.7B. That gives the company room to invest without stretching the balance sheet.
One data point in the quarterly balance sheet shows debt at $304M as of 2026-04-30, which conflicts with annual debt data of $3.35B and management’s stated net leverage ratio of 0.7 turns in Q2. The annual and debt schedule figures are more consistent with the broader record, so the cleaner takeaway is that leverage remains modest rather than nonexistent. In other words, the balance sheet is strong, but not magically debt-free overnight.
Agilent operates in the life sciences tools and services market, where external estimates place the addressable market at roughly $60B to $165B today depending on scope. Mordor Intelligence estimates the global life science tools market at $164.47B in 2026, growing to $230.07B by 2031, a 6.93% CAGR. MarketsandMarkets estimates the narrower life science instrumentation market at $63.40B in 2025, growing to $92.53B by 2031, a 6.5% CAGR.
Agilent’s own framing is also useful. Investor materials put total company TAM at $80B, growing 4% to 6%, including $25B in pharma and biopharma, $20B in clinical and diagnostics, $14B in academic and government, $8B in chemicals and advanced materials, $6B in food, and $7B in environmental and forensics. Against FY2025 revenue of $6.948B, that leaves a long runway if the company keeps taking share.
The industry is shifting toward recurring revenue, managed workflows, and software-enabled lab operations. Services are one of the fastest-growing categories, with Mordor estimating 11.35% CAGR. That trend favors Agilent because CrossLab already gives it a large recurring base. It also favors companies that can bundle instruments, consumables, software, and compliance support into one relationship. Agilent checks that box.
End-market demand is recovering unevenly, and Agilent’s Q2 FY2026 results reflect that. Pharma grew 6%, chemicals and advanced materials grew 8%, diagnostics and clinical grew 11%, and environmental forensics grew 13%. Food declined 3% due to funding delays in China and India, while academia and government declined 5%. This is a market with real pockets of strength, not a uniform boom.
The strongest near-term demand signals sit in biopharma, diagnostics, semiconductor-related spectroscopy, and forensics. Management also cited GLP-1 exposure growing about 20% year to date and continued replacement-cycle momentum in instruments. Those are attractive pockets because they combine secular demand with practical workflow spending.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Agilent serves a broad customer base, but the mix is not random. In the FY2025 investor presentation, pharma represented 37% of revenue, diagnostics and clinical 15%, chemicals and advanced materials 22%, environmental and forensics 10%, food 9%, and academia and government 7%. That mix gives the company meaningful exposure to regulated and mission-critical workflows, while limiting dependence on any single customer class.
Pharma and biotech are the most important customers because they buy across instruments, consumables, software, and services. In Q2 FY2026, biotech posted another quarter of low double-digit growth, led by large caps, while small to mid caps showed improving demand signals. Management also said GLP-1-related demand was up about 20% year to date. Those are high-value customers with long workflow tails.
Clinical and diagnostics customers are another attractive group. Cancer diagnostics and pathology reagents grew low double digits in Q2 FY2026, supported by the Omnis family and an expanding installed base. These customers care about reliability, compliance, and throughput. That tends to support recurring consumables and service revenue once the platform is in place.
Applied customers in semiconductors, chemicals, food, environmental testing, and forensics add diversification. In Q2 FY2026, semiconductor-related spectroscopy demand was strong enough to drive double-digit performance in that business, while forensics grew more than 50% with help from the TSA contract and tender wins in Asia and Europe. These customers are less correlated with biopharma cycles, which helps smooth demand.
The weak spot remains academia and government. Management said that end market declined 5% in Q2 FY2026 and had been expected to stay soft. That is not ideal, but it is also only 7% of revenue based on the FY2025 presentation. Agilent can absorb that pressure as long as pharma, diagnostics, and applied markets stay healthy.
Agilent competes with Thermo Fisher Scientific, Danaher, Waters, Bruker, Shimadzu, Bio-Rad, Revvity, Roche, and QIAGEN across different product lines and workflows. In its own filings, the company identifies Bruker, Danaher units such as AB Sciex and Leica Biosystems, Shimadzu, Thermo Fisher, Waters, Roche Ventana, Twist Bioscience, and Avecia/Nitto Denko as principal competitors depending on the product line.
The company’s advantage versus smaller specialists is breadth. It can sell instruments, columns, consumables, software, and service into the same lab. Its challenge versus larger peers is scale. Danaher reported 2025 sales of $24.6B, with Life Sciences at $7.3B and Diagnostics at $10.0B, which shows the size gap. Thermo Fisher is larger still. Agilent cannot out-muscle those companies across every category.
Instead, Agilent competes on workflow fit, customer support, and installed-base monetization. Recent results suggest it is winning enough of those battles. Management cited share gains across key workflows and geographies, low double-digit growth in LC and LCMS, strong traction in diagnostics, and outsized growth in forensics. The company also said industry market share data validated share expansion in major geographies.
CrossLab is a particularly useful differentiator. Many competitors can sell an instrument. Fewer can wrap that instrument in a broad service, compliance, software, and consumables relationship at global scale. That is where Agilent’s model becomes sticky. It is less a one-time equipment sale and more a long lease on customer inconvenience.
Peer-multiple comparison data is not available in the provided dataset, so the valuation discussion cannot lean on exact peer medians. Still, the competitive picture is clear enough: Agilent is a high-quality but smaller-scale incumbent that is executing well and taking share in selected workflows, while operating in a field dominated by a few giants.
Macro conditions matter for Agilent because instrument demand is tied to customer capex, while consumables and services are tied more to lab activity. The recent recovery has been helped by improving end-market conditions, replacement cycles, and regional supply-chain investment. In the FY2025 investor presentation, management said the Americas and Europe were benefiting from regionalization of supply chains, which drove investment.
Geopolitics is a real operating variable. The 10-K notes that higher tariffs and shipping costs hurt FY2025 gross margin, which fell to 52.4% from 54.3% in FY2024. Management also cited trade-policy changes, tariff uncertainty, and geopolitical tensions as risks. In Q2 FY2026, however, the company said its tariff task force fully mitigated the incremental tariffs that began in late spring through manufacturing moves and targeted price adjustments.
China remains a mixed factor. In Q2 FY2026, China revenue declined 9%, a bit worse than management expected, though first-half China was roughly flat and in line with the full-year guide. That matters because China can swing demand for instruments, food testing, and academic spending. Agilent’s launch of a China Innovation Center shows commitment to the market, but the near-term demand picture there is softer than in the Americas or Europe.
The Middle East conflict also entered the story through logistics and inflationary pressure. Management said the conflict created logistics challenges and material shortages, but Ignite helped the company respond quickly and absorb inflationary impacts within second-half guidance. That is encouraging, though it does not make the risk disappear. It just means Agilent has a better umbrella than some peers when the weather turns ugly.
On the demand side, broader life sciences trends remain favorable. AI-enabled drug development, multi-omics expansion, diagnostics adoption, and manufacturing buildout all support demand for analytical tools and quality-control workflows. Management explicitly tied AI adoption in pharma to future wet-lab investment and said a higher number of approvals moving through the drug pipeline would benefit Agilent’s downstream manufacturing QA/QC position.
Agilent ended FY2025 with $1.15B in free cash flow and a 6.01% FCF yield, underscoring a cash-generative balance sheet even as valuation stays elevated.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →FY2025 revenue rose to $6.948B and Q2 FY2026 sales reached $1.83B, while non-GAAP EPS climbed 14% year over year to $1.49.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted FY2026 guidance to $7.39B-$7.49B in revenue and $6.00-$6.10 in non-GAAP EPS after a quarter of 10.0% reported growth.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Agilent trades at 25.57x trailing earnings, 19.38x forward earnings, and 4.83x EV/revenue, so the market is already pricing in continued recovery.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The stock’s 52-week range of $108.35 to $159.62 shows how sharply sentiment has swung, and the report favors buying on pullbacks rather than chasing strength.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Agilent Technologies(A) is doing a lot right. Revenue is growing again, margins are expanding, guidance is moving higher, and the company is proving that Ignite is more than a slogan. CrossLab gives the business recurring revenue support, diagnostics adds a higher-value clinical angle, and Applied Markets brings differentiated exposure to semiconductors, forensics, and industrial testing.
This is not a turnaround story and it is not a moonshot. It is a quality industrial-healthcare hybrid with real moats, disciplined execution, and enough growth to compound value over a medium-term horizon. The stock deserves respect, but also price discipline. With this report’s fair value estimate of $148, Agilent remains a Buy for investors who want a durable operator in life science tools and are willing to let the business do the heavy lifting.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →
Agilent Technologies, Inc. (A) climbs after hours after topping quarterly earnings and revenue estimates and raising full-year guidance. The rally reflects stronger demand, margin expansion, and improved execution across the company’s life sciences, diagnostics, and applied markets businesses.
Mortgage rates edged higher to 6.6%, but borrowers still rushed in, with applications jumping 10.8% for the week. The rebound shows housing demand remains sensitive to rates, even as affordability stays tight and higher Treasury yields keep mortgage relief elusive.
U.S. inflation reaccelerated in May, with headline CPI rising to 4.2% year over year as energy costs did most of the damage. Core CPI stayed cooler than feared at 2.9%, easing market panic but keeping the Fed on a higher-for-longer path.